Ordin nr. 1301/500/2008 din 11 iulie 2008 Partea a ii-a
Se aplică tuturor denumirilor comerciale, formelor farmaceutice şi concentraţiilor corespunzătoare DCI-ului
Yüklə 4,39 Mb.
|
- Bu səhifədəki naviqasiya:
- SUBLISTA C1 - G22 BOLI ENDOCRINE (GUŞA ENDEMICĂ, INSUFICIENŢA SUPRARENALĂ CRONICĂ, DIABETUL INSIPID, MIXEDEMUL ADULTULUI, TUMORI HIPOFIZARE CU EXPANSIUNE SUPRASELARĂ ŞI TUMORI NEUROENDOCRINE).
- Prevenirea apariţiei lactaţiei în lăuzie din motive medicale
- Hiperprolactinemia patologică pentru care nu este indicată intervenţia chirurgicală
- SUBLISTA C1 - G23 BOALA WILSON. ______________________________________________________________________________ | 537 |M01CC01 | PENICILLAMINUM**(4)
- SUBLISTA C1 - G25 BOALA CRONICA DE RINICHI - FAZA PREDIALIZA. ______________________________________________________________________________ | 538 |A11CC07
| Se aplică tuturor denumirilor comerciale, formelor farmaceutice şi concentraţiilor corespunzătoare DCI-ului.
________________________________________________________________________________ DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ M01AB05 DICLOFENACUM COMPR. FILM. ELIB. PREL 100 mg DICLOTARD(R) 100 mg 100 mg TERAPIA SA REFEN(R) RETARD 100 mg HEMOFARM S.R.L VOLTAREN(R) RETARD 100 mg NOVARTIS PHARMA GMBH
CLAFEN 100 mg 100 mg ANTIBIOTICE SA DICLOFENAC 100 mg 100 mg SINTOFARM SA DICLOFENAC SODIC 100 mg 100 mg MAGISTRA C & C DICLOGESIC 100 SUPOZITOARE 100 mg DAR AL DAWA PHARMA SRL EPIFENAC 100 mg E.I.P.I.CO. MED S.R.L. VOLTAREN(R) 100 mg NOVARTIS PHARMA GMBH
TRATUL 120 120 mg GEROT PHARMAZEUTIKA GMBH M01AB05 DICLOFENACUM CAPS. ELIB. PREL. 150 mg DICLOREUM 150 mg 150 mg ALFA WASSERMANN SPA M01AB05 DICLOFENACUM COMPR. FILM. GASTROREZ. 25 mg RHEUMAVEK 25 mg FARAN LABORATORIES S.A. VOLTAREN(R) 25 25 mg NOVARTIS PHARMA GMBH
EPIFENAC 25 mg E.I.P.I.CO. MED S.R.L. M01AB05 DICLOFENACUM DRAJ. GASTROREZ. 25 mg DICLOFENAC 25 mg 25 mg ARENA GROUP SA M01AB05 DICLOFENACUM SOL. INJ. 25 mg/ml RHEUMAVEK 25 mg/ml FARAN LABORATORIES S.A. VOLTAREN(R) 25 mg/ml NOVARTIS PHARMA GMBH
TRATUL(R) 30 mg/ml GEROT PHARMAZEUTIKA GMBH M01AB05 DICLOFENACUM CAPS. GASTROREZ. 50 mg TRATUL 50 50 mg GEROT PHARMAZEUTIKA GMBH M01AB05 DICLOFENACUM COMPR. FILM. GASTROREZ. 50 mg CLAFEN 50 mg 50 mg ANTIBIOTICE SA DICLOFENAC 50 mg 50 mg AC HELCOR PHARMA SRL VOLTAREN(R) 50 50 mg NOVARTIS PHARMA GMBH M01AB05 DICLOFENACUM DRAJ. 50 mg VOLTAREN RAPID(R) 50 mg NOVARTIS PHARMA GMBH M01AB05 DICLOFENACUM DRAJ. GASTROREZ. 50 mg DICLOFENAC 50 mg 50 mg ARENA GROUP SA M01AB05 DICLOFENACUM SUPOZ. 50 mg VOLTAREN(R) 50 mg NOVARTIS PHARMA GMBH M01AB05 DICLOFENACUM SUPOZ. 60 mg TRATUL 60 60 mg GEROT PHARMAZEUTIKA GMBH M01AB05 DICLOFENACUM COMPR. ELIB. MODIF. 75 mg DICLAC(R) 75 ID 75 mg HEXAL AG M01AB05 DICLOFENACUM SOL. INJ. 75 mg DICLAC 75 mg HEXAL AG VURDON 75 mg HELP S.A. PHARMACEUTICALS
ALMIRAL 75 mg/3 ml MEDOCHEMIE LTD. DICLOFENAC 75 mg 75 mg/3 ml TERAPIA SA DICLOFENAC AL I.M. 75 mg/3 ml ALIUD PHARMA GMBH & CO.KG ________________________________________________________________________________
| 525 |G02CB03| CABERGOLINUM** | Protocol: G001C | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ G02CB03 CABERGOLINUM COMPR. 0.5 mg DOSTINEX 0.5 mg PFIZER EUROPE MA EEG
DOSTINEX 0.5 mg PFIZER EUROPE MA EEG Prescriere limitată: Prevenirea apariţiei lactaţiei în lăuzie din motive medicale Cod restricţie 2659: Hiperprolactinemia patologică pentru care nu este indicată intervenţia chirurgicală Cod restricţie 2660: Hiperprolactinemia patologică pentru care a fost utilizat tratament chirurgical dar cu rezultate incomplete ________________________________________________________________________________ ______________________________________________________________________________ | 526 |H01AX01| PEGVISOMANTUM**** | Protocol: H012E | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ H01AX01 PEGVISOMANTUM LIOF. + SOLV. PT. SOL. 10 mg INJ. SOMAVERT 10 mg 10 mg PFIZER LTD. H01AX01 PEGVISOMANTUM LIOF. + SOLV. PT. SOL. 20 mg INJ.
SOMAVERT 20 mg 20 mg PFIZER LTD. ________________________________________________________________________________ ______________________________________________________________________________ | 527 |H01BA02| DESMOPRESSINUM | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ H01BA02 DESMOPRESSINUM COMPR. 0.2 mg MINIRIN 0,2 mg 0.2 mg FERRING AB
MINIRIN 0,2 mg 0.2 mg FERRING AB ________________________________________________________________________________
| 528 |H01CB02| OCTREOTIDUM**** | Protocol: H008E | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ H01CB02 OCTREOTIDUM COMPR. 100 mg SANDOSTATIN(R) 0.1 mg/ml NOVARTIS PHARMA GMBH
INJ. (I.M.) CU ELIB. PRELUNG. SANDOSTATIN LAR 10 mg 10 mg NOVARTIS PHARMA GMBH H01CB02 OCTREOTIDUM PULB. + SOLV. PT. SUSP. 20 mg INJ. (I.M.) CU ELIB. PRELU SANDOSTATIN LAR 20 mg 20 mg NOVARTIS PHARMA GMBH H01CB02 OCTREOTIDUM PULB. + SOLV. PT. SUSP. 30 mg INJ. (I.M.) CU ELIB. PRELUNG. SANDOSTATIN LAR 30 mg 30 mg NOVARTIS PHARMA GMBH ________________________________________________________________________________
| 529 |H01CB03| LANREOTIDUM**** | Protocol: H005E;| | | | | H006C | |_______|_______|____________________________________________|_________________| ________________________________________________________________________________ DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ H01CB03 LANREOTIDUM LIOF. PT. SOL. INJ. + 30 mg SOLV. SOMATULINE(R) PR 30 mg 30 mg BEAUFOUR IPSEN PHARMA ________________________________________________________________________________ ______________________________________________________________________________ | 530 |H02AA02| FLUDROCORTISONUM | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ H02AA02 FLUDROCORTISONUM COMPR. 0.1 mg ASTONIN H 0.1 mg MERCK KGAA ________________________________________________________________________________ ______________________________________________________________________________ | 531 |H02AB06| PREDNISOLONUM | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ H02AB06 PREDNISOLONUM LIOF. + SOLV. PT. SOL. 250 mg INJ. SOLU - DECORTIN H 250 250 mg MERCK KGAA H02AB06 PREDNISOLONUM LIOF. + SOLV. PT. SOL. 50 mg INJ.
SOLU - DECORTIN H 50 50 mg MERCK KGAA ________________________________________________________________________________ ______________________________________________________________________________ | 532 |H02AB07| PREDNISONUM | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ H02AB07 PREDNISONUM COMPR. 5 mg N - PREDNISON 5 mg MEDUMAN SA PREDNISON 5 mg 5 mg SINTOFARM SA PREDNISON ARENA 5 mg 5 mg ARENA GROUP SA PREDNISON GEDEON RICHTER 5 mg 5 mg GEDEON RICHTER ROMANIA SA PREDNISON MAGISTRA 5 mg 5 mg MAGISTRA C & C ________________________________________________________________________________ ______________________________________________________________________________ | 533 |H02AB09| HYDROCORTISONUM | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ H02AB09 HYDROCORTISONUM LIOF. + SOLV. PT. SOL. 100 mg INJ. HYDROCORTISONE 100 mg 100 mg HEMOFARM S.R.L HYDROCORTISONE SUCCINAT SODIC 100 mg E.I.P.I.CO. MED S.R.L. H02AB09 HYDROCORTISONUM SOL. INJ. I.V. 25 mg/5 ml HIDROCORTIZON HEMISUCCINAT 25 mg/5 ml ZENTIVA S.A. H02AB09 HYDROCORTISONUM LIOF. PT. SOL. INJ. + 500 mg SOLV.
HYDROCORTISONE 500 mg 500 mg HEMOFARM S.R.L. ________________________________________________________________________________ ______________________________________________________________________________ | 534 |H03AA01| LEVOTHYROXINUM | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ H03AA01 LEVOTHYROXINUM COMPR. 100 µg EUTHYROX(R) 100 100 µg MERCK KGAA L-THYROXIN 100 BERLIN-CHEMIE 100 µg BERLIN CHEMIE AG MENARINI GROUP
EUTHYROX(R) 200 200 µg MERCK KGAA H03AA01 LEVOTHYROXINUM COMPR. 25 µg EUTHYROX(R) 25 25 µg MERCK KGAA H03AA01 LEVOTHYROXINUM COMPR. 50 µg EUTHYROX(R) 50 50 µg MERCK KGAA L-THYROXIN 50 50 µg BERLIN CHEMIE AG MENARINI GROUP
________________________________________________________________________________ ______________________________________________________________________________ | 535 |H03CA01| KALII IODIDUM | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ H03CA01 KALII IODIDUM COMPR. 100 µg JODID 100 100 µg MERCK KGAA H03CA01 KALII IODIDUM COMPR. 200 µg JODID 200 200 µg MERCK KGAA ________________________________________________________________________________ ______________________________________________________________________________ | 536 |G02CB01| BROMOCRIPTINUM | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ G02CB01 BROMOCRIPTINUM DRAJ. 2.5 mg BROCRIPTIN 2.5 mg BIOFARM SA
Prescriere limitată: Hiperprolactinemia patologică pentru care tratamentul chirurgical utilizat a dus la rezultate incomplete; ________________________________________________________________________________ SUBLISTA C1 - G23 BOALA WILSON. ______________________________________________________________________________ | 537 |M01CC01| PENICILLAMINUM**(4) | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ M01CC01 PENICILLAMINUM ________________________________________________________________________________
| 538 |A11CC07| PARICALCITOLUM** | Protocol: A005E | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ A11CC07 PARICALCITOLUM SOL. INJ. 5 µg/ml ZEMPLAR 5 µg/ml ABBOTT LABORATORIES S.A. ________________________________________________________________________________ ______________________________________________________________________________ | 539 |B03AC02| COMPLEX DE HIDROXID DE FER (III) SUCROZA** | Protocol: A010N | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ B03AC02 COMPLEX DE HIDROXID SOL. INJ./PERF. 20 mg/ml DE FER (III) SUCROZA VENOFER(R) 20 mg/ml VIFOR FRANCE S.A. ________________________________________________________________________________
| 540 |B03XA01| EPOETINUM ALFA** | Protocol: B010N | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ B03XA01 EPOETINUM ALFA SOL. INJ. 10000 ui/ml EPREX(R) 10000 UI 10000 ui/ml JOHNSON & JOHNSON D.O.O.
EPOKINE 1000 UI/0,5 ml 1000 UI/0.5 ml RENAMED FARMA S.R.L. EPREX(R) 1000 UI 1000 ui/0.5 ml JOHNSON & JOHNSON D.O.O.
EPOPHAR 2000 U.I. 2000 UI GULF PHARMACEUTICAL IND. S.R.L.
EPOKINE 2000 UI/0,5 ml 2000 UI/0.5 ml RENAMED FARMA S.R.L. EPREX(R) 2000 UI 2000 ui/0.5 ml JOHNSON & JOHNSON D.O.O.
EPOKINE 2000 UI/1 ml 2000 UI/1 ml RENAMED FARMA S.R.L. B03XA01 EPOETINUM ALFA SOL. INJ. 3000 ui/0.3 ml EPREX(R) 3000 UI 3000 ui/0.3 ml JOHNSON & JOHNSON D.O.O. B03XA01 EPOETINUM ALFA SOL. INJ. 40000 UI EPREX(R) 40000 UI 40000 UI JOHNSON & JOHNSON D.O.O. B03XA01 EPOETINUM ALFA SOL. INJ. 4000 UI EPOPHAR 4000 U.I. 4000 UI GULF PHARMACEUTICAL IND. S.R.L. B03XA01 EPOETINUM ALFA SOL. INJ. 4000 ui/0.4 ml EPOKINE 4000 UI/0,4 ml 4000 UI/0.4 ml RENAMED FARMA S.R.L. EPREX(R) 4000 UI 4000 ui/0.4 ml JOHNSON & JOHNSON D.O.O. B03XA01 EPOETINUM ALFA SOL. INJ. 4000 UI/1 ml EPOKINE 4000 UI/1 ml 4000 UI/1 ml RENAMED FARMA S.R.L. ________________________________________________________________________________
| 541 |B03XA01| EPOETINUM BETA** | Protocol: B009N | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ B03XA01 EPOETINUM BETA SOL. INJ. ÎN SERINGĂ PREUMPLUTĂ NEORECORMON 10000 UI 10000 UI/0,6ml ROCHE REGISTRATION L B03XA01 EPOETINUM BETA SOL. INJ. ÎN SERINGĂ PREUMPLUTĂ NEORECORMON 1000 UI 1000 UI/0,3 ml ROCHE REGISTRATION L
PREUMPLUTĂ NEORECORMON 2000 UI 2000 UI/0,3 ml ROCHE REGISTRATION L
PREUMPLUTĂ NEORECORMON 30000 UI/0,6 ml 30000 UI/0,6 ml ROCHE REGISTRATION LTD.
PREUMPLUTĂ NEORECORMON 4000 UI 4000 UI/0,3 ml ROCHE REGISTRATION L
PREUMPLUTĂ NEORECORMON 5000 UI 5000 UI/0,3 ml ROCHE REGISTRATION L
PREUMPLUTĂ NEORECORMON 500 UI 500 UI/0,3 ml ROCHE REGISTRATION L ________________________________________________________________________________ ______________________________________________________________________________ | 542 |B03XA02| DARBEPOETINUM ALFA** | Protocol: B011N | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ B03XA02 DARBEPOETINUM ALFA SOL. INJ. ÎN SERINGĂ 10 µg/0.4 ml PREUMPLUTĂ ARANESP 10 µg/0.4 ml 10 µg/0.4 ml AMGEN EUROPE BV B03XA02 DARBEPOETINUM ALFA SOL. INJ. ÎN SERINGĂ 100 µg/0.5 ml PREUMPLUTĂ ARANESP 100 µg/0.5 ml 100 µg/0.5 ml AMGEN EUROPE BV B03XA02 DARBEPOETINUM ALFA SOL. INJ. ÎN SERINGĂ 15 µg/0.375 ml PREUMPLUTĂ ARANESP 15 µg/0.375 ml 15 µg/0.375 ml AMGEN EUROPE BV B03XA02 DARBEPOETINUM ALFA SOL. INJ. ÎN SERINGĂ 150 µg/0.3 ml PREUMPLUTĂ ARANESP 150 µg/0.3 ml 150 µg/0.3 ml AMGEN EUROPE BV
PREUMPLUTĂ ARANESP 20 µg/0.5 ml 20 µg/0.5 ml AMGEN EUROPE BV
PREUMPLUTĂ ARANESP 30 µg/0.3 ml 30 µg/0.3 ml AMGEN EUROPE BV
PREUMPLUTĂ ARANESP 300 µg/0.6 ml 300 µg/0.6 ml AMGEN EUROPE BV
PREUMPLUTĂ ARANESP 40 µg/0.4 ml 40 µg/0.4 ml AMGEN EUROPE BV
PREUMPLUTĂ ARANESP 50 µg/0.5 ml 50 µg/0.5 ml AMGEN EUROPE BV
PREUMPLUTĂ ARANESP 500 µg/ml 500 µg/ml AMGEN EUROPE BV
PREUMPLUTĂ ARANESP 60 µg/0.3 ml 60 µg/0.3 ml AMGEN EUROPE BV
PREUMPLUTĂ ARANESP 80 µg/0.4 ml 80 µg/0.4 ml AMGEN EUROPE BV ________________________________________________________________________________ ______________________________________________________________________________ | 544 |C09CA04| IRBESARTANUM** | Protocol: C008N | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ C09CA04 IRBESARTANUM COMPR. FILM. 150 mg APROVEL 150 mg 150 mg SANOFI PHARMA - BRISTOL MYERS SQUIBB C09CA04 IRBESARTANUM COMPR. FILM. 300 mg APROVEL 300 mg 300 mg SANOFI PHARMA - BRISTOL MYERS SQUIBB ________________________________________________________________________________ ______________________________________________________________________________ | 545 |H02AB07| PREDNISONUM | Protocol: H002N | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ H02AB07 PREDNISONUM COMPR. 5 mg N-PREDNISON 5 mg MEDUMAN SA PREDNISON 5 mg 5 mg SINTOFARM SA PREDNISON ARENA 5 mg 5 mg ARENA GROUP SA PREDNISON GEDEON RICHTER 5 mg 5 mg GEDEON RICHTER ROMANIA SA PREDNISON MAGISTRA 5 mg 5 mg MAGISTRA C & C ________________________________________________________________________________ ______________________________________________________________________________ | 546 |L01AA01| CYCLOPHOSPHAMIDUM | Protocol: L027N | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ L01AA01 CYCLOPHOSPHAMIDUM DRAJ. 50 mg ENDOXAN(R) 50 mg 50 mg BAXTER ONCOLOGY GMBH ________________________________________________________________________________ ______________________________________________________________________________ | 547 |L04AA01| CICLOSPORINUM* | Protocol: L028N | |_______|_______|____________________________________________|_________________|
Yüklə 4,39 Mb. Dostları ilə paylaş:
|